Study Description

A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effect on cognitive performance, safety, and tolerability of  investigational medication for 24 weeks in patient with mild to moderate Alzheimer’s Disease on stable donepezil (Aricept®) therapy.

Length of study: up to 38 weeks

Number of office visits: up to 10 visits

Qualified participants will receive study medication and study related services at no cost. In addition, participants will be reimbursed for time and travel.

Study inclusion/exclusion criteria

The potential participant must:

• Easily read and understand English
• Be at least 55 years old
• Be currently on a stable dose of donepezil (Aricept®, 5 or 10mg) for at least 4 months.
• Not have serious eye problems
• Not currently on excluded medications such as memantine (Namenda®) or thiazidie diuretics

Contact us at:

California Neuroscience Research Medical Group, Inc.
4835 Van Nuys Blvd., Suite 104
Sherman Oaks, CA 91403 USA
(818) 990-2671
tara@cnrmg.com
 

[Home] [For Patients] [Studies] [FAQ] [Sponsor Overview] [Contact Us]